DYRK1A and prostate cancer: Prostate cancer is most likely to develop bone metastases, and prostate cancer-derived miR-378a-3p-containing EVs promote osteolysis by activating the Dyrk1a/Nfatc1/Angptl2 axis in bone marrow macrophages during tumor bone metastasis [208].